AMED Amedeo Res

RNS No 5422t
CHIROSCIENCE GROUP PLC
12th August 1998 
                                    
                                    
          CHIROSCIENCE ANNOUNCES NEW CHAIRMAN AND BOARD CHANGE
                                    
Mr  Hugh Collum has been appointed a Director of Chiroscience Group  plc
with effect from 1st October 1998 and will succeed Lord Henry Chilver as
Chairman  with  effect from the same date.  Lord Chilver  announced  his
intention to retire as Chairman and as a Director in the 1998 Report and
Accounts,  following more than   three successful years  overseeing  the
transition  of  Chiroscience  into one  of  the  UK's  leading  emerging
pharmaceutical  companies.  The Board wishes to thank Lord  Chilver  for
his  considerable  commitment  to  Chiroscience  during  his  period  as
Chairman.
 
Hugh  Collum  is currently Executive Vice President and Chief  Financial
Officer  of  SmithKline Beecham plc.  He is a Non-Executive Director  of
M&G  Group  plc, Whitehead Mann Group plc and Safeway  plc.    Prior  to
joining  Beecham in 1987, Hugh was Finance Director of Cadbury Schweppes
plc.   He was a member of the Cadbury Committee on the Financial Aspects
of  Corporate Governance and was also Chairman of The Hundred  Group  of
Finance Directors for 1990/92.
 
Dr  Robert  Jackson has been appointed Executive Director, Research  and
Development   for  Chiroscience  Group  plc,  broadening  his   existing
responsibilities.  Bob was appointed a Director in July  1997,  when  he
joined  Chiroscience from Agouron Pharmaceuticals Inc to be  responsible
for  all  Chiroscience  R&D  Ltd's UK activities.   He  will  also  take
responsibility for Chiroscience R&D activities in Seattle, directing all
work  from  'gene  to  drug'.  Dr Jackson will host  an  R&D  Update  on
September  29th  in London and October 9th in New York,  describing  the
Group's  progress in gene and drug discovery and providing an update  on
the development pipeline.
 
Following  the  successful integration of the scientific  activities  in
Seattle and Cambridge, Dr David Galas has indicated his wish to spend  a
greater  proportion  of  his time in an academic environment  and,  with
effect  from  31st  August 1998, will move to a  part-time  position  to
enable  him to become Chief Academic Officer and Vice-President  of  the
Keck Graduate Institute of Applied Life Sciences, Claremont, California.
David will resign as a Director of Chiroscience Group plc from the above
date,  though  will  continue to play an active  advisory  role  in  the
scientific  activities  conducted  in  the  Chiroscience's  facility  in
Seattle.   In  this  role he will report to Dr Robert  Jackson  and  the
President  of  the  newly-formed Rapigene  Inc.,  whose  appointment  is
anticipated shortly.
 
The  Board  thanks  David for his formative role  in  the  creation  and
development  of Chiroscience's genomic capabilities and for  his  active
role  in  the  integration of the scientific activities in  Seattle  and
Cambridge.   These have helped to create a valuable drug  discovery  and
development capability which is unique within the sector.
 
 
For further information contact:
 
Dr John Padfield, Chief Executive
Rebecca Iveson, Media and Investor Relations
Tel: +44 (0) 1223 420430
http://www.chiroscience.com
 
Giles Sanderson
Financial Dynamics
Tel: +44 (0) 171 831 3113
 
 
NOTES TO EDITORS
 
Chiroscience Group plc
Chiroscience Group plc is an emerging pharmaceutical company which  uses
its  diverse technology platform to discover and develop novel medicines
for  improved  healthcare.  It is listed on the London  Stock  Exchange.
The  Group  has three principal activities: Chiroscience R&D;  Rapigene;
and ChiroTech.
 
The Chiroscience R&D drug discovery and development activities are based
in  Cambridge and Stevenage, England, and Seattle, Washington, USA   and
encompass skills from gene-based target research  and molecular biology,
through chiral-based, combinatorial, medicinal, and process chemistries,
to clinical development and registration.  The focus of activities is on
the  discovery  and development of innovative small molecule  drugs  and
related  diagnostics  with a therapeutic focus on cancer,  inflammation,
pain, osteoporosis and autoimmune diseases.
 
Rapigene   is  involved  in  the  creation  and  provision  of   genomic
technologies  and  services to partner companies and  to  Chiroscience's
drug  discovery  programmes.  Its DNA analysis systems comprise  of  DNA
hybridization, DNA arrays and mass spectrometry tags.
 
ChiroTech  provides chiral technology services to customers  within  the
pharmaceutical and related industries, including Chiroscience R&D.
 
 
END

BOAFCDCBODKDNFD

Grafico Azioni Amedeo Res (LSE:AMED)
Storico
Da Giu 2024 a Lug 2024

Grafico Azioni Amedeo Res (LSE:AMED)
Storico
Da Lug 2023 a Lug 2024